Hepatocellular Carcinoma (HCC) Clinical Trials in Wuhan, Hubei
6 recruitingWuhan, Hubei, China
Showing 1–6 of 6 trials
Recruiting
Phase 2
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Tongji Hospital94 enrolled1 locationNCT07413354
Recruiting
Phase 2
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Hepatocellular Carcinoma (HCC)
Abbisko Therapeutics Co, Ltd141 enrolled51 locationsNCT07327034
Recruiting
Phase 2
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Wei Zhang27 enrolled1 locationNCT07154082
Recruiting
Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
Hepatocellular Carcinoma (HCC)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology350 enrolled1 locationNCT07059936
Recruiting
Phase 1
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma (HCC)
AbbVie20 enrolled11 locationsNCT06487559
Recruiting
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
Hepatocellular Carcinoma (HCC)
Tongji Hospital50 enrolled1 locationNCT06653062